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Abstract: Gastric cancer is a major health burden and is the fifth most common malignancy and the
third most common cause of death from cancer worldwide. Development of gastric cancer involves
several aspects, including host genetics, environmental factors, and Helicobacter pylori infection.
There is increasing evidence from epidemiological studies of the association of H. pylori infection
and specific virulence factors with gastric cancer. Studies in animal models indicate H. pylori is a
primary factor in the development of gastric cancer. One major virulence factor in H. pylori is the
cytotoxin-associated gene A (cagA), which encodes the CagA protein in the cag pathogenicity island
(cag PAI). Meta-analysis of studies investigating CagA seropositivity irrespective of H. pylori status
identified that CagA seropositivity increases the risk of gastric cancer (OR = 2.87, 95% CI: 1.95–4.22)
relative to the risk of H. pylori infection alone (OR = 2.31, 95% CI: 1.58–3.39). Eradicating H. pylori
is a strategy for reducing gastric cancer incidence. A meta-analysis of six randomised controlled
trials (RCTs) suggests that searching for and eradicating H. pylori infection reduces the subsequent
incidence of gastric cancer with a pooled relative risk of 0.66 (95% CI: 0.46–0.95). The introduction
in regions of high gastric cancer incidence of population-based H. pylori screening and treatment
programmes, with a scientifically valid assessment of programme processes, feasibility, effectiveness
and possible adverse consequences, would impact the incidence of H. pylori-induced gastric cancer.
Given the recent molecular understanding of the oncogenic role of CagA, targeting H. pylori screening
and treatment programmes in populations with a high prevalence of H. pylori CagA-positive strains,
particularly the more oncogenic East Asian H. pylori CagA strains, may be worth further investigation
to optimise the benefits of such strategies.
Keywords: Helicobacter pylori; gastric cancer; CagA; epidemiology; randomised controlled trial
Key Contribution: This review article covers the epidemiology of Helicobacter pylori infection and
gastric cancer globally. One major virulence factor in H. pylori is the cytotoxin-associated gene A
(cagA), which encodes the CagA protein in the cag pathogenicity island (cag PAI). The review also
describes the epidemiological evidence associating infection with CagA positive H. pylori strains
with increased risk of gastric cancer. Factors such as high dietary salt intake and low host iron status,
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known risk factors for gastric cancer, are associated with increased H. pylori cagA gene expression
and CagA protein.
1. Introduction: The Global Burden of Gastric Cancer
Gastric cancer is the fifth most common malignancy in the world (after lung, breast, colorectal and
prostate cancers). Globally, nearly one million (952,000) new cases and 723,000 deaths were estimated
to have occurred from this disease in 2012 [1]. It accounts for 7% of new cancer cases and 9% of all
cancer deaths worldwide (Figure 1) [1]. The distribution map for the incidence of male gastric cancer
shows wide variation between geographic regions with the highest rates observed in Asia, Central
and South America and Eastern Europe (Figure 2). The pattern of distribution for females is almost
identical to that for males although female rates are usually around half those in males (data not
shown, [1]). Over 70% of new gastric cancer cases that occurred in 2012 were in less developed regions
of the world with Asia contributing approximately 72% of the global burden and almost half of the
cases in the world occurring in China (Figure 3) [1].
Figure 1. Estimated frequency of new cancer cases and deaths Worldwide in 2012, both sexes combined
(Source: GLOBOCAN 2012, adapted from [1], 2013, International Agency for Research on Cancer).
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Figure 2. Estimated age-standardised (world) incidence rates of gastric cancer per 100,000 by country
among males in 2012 (Source: GLOBOCAN 2012, adapted from [1], 2013, International Agency for
Research on Cancer).
Figure 3. Gastric cancer: number of new cases and deaths with proportions by major regions (both
genders combined) in 2012 (Source: GLOBOCAN 2012, adapted from [1], 2013, International Agency
for Research on Cancer).
Using the high-quality cancer registry data from the Cancer Incidence in Five Continents Volume
XI (CI5 XI) [2], Table 1 identifies populations with some of the highest and lowest observed male gastric
cancer rates in the world for the period 2008–2012. The magnitude of the difference is over 14-fold as
seen by comparing the incidence rates in populations within China, the Republic of Korea and Japan
(at or over 70 per 100,000) with those in several African, Asian and USA populations, which did not
exceed 5 per 100,000. Overall, global patterns of incidence and mortality are very similar to each other
because prognosis following a diagnosis of gastric cancer is usually poor [3]. However, mortality rates
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in Japan and the Republic of Korea are, in comparison with other populations, considerably lower
than the corresponding incidence rates. This likely reflects the impact of screening and early diagnosis
in these countries.
Table 1. Cancer registries with high and low age-standardised (world) incidence rates of gastric cancer,
males, 2008–2012 (Source: Cancer Incidence in Five Continents, Volume XI adapted from [2], 2017,
International Agency for Research on Cancer).
Registry ASR Registry ASR
China, Yanting County 144.6 Jordan, Jordanians 5.0
Japan, Yamagata 77.4 USA Florida, White 4.6
Republic of Korea, Daejeon 68.8 Philippines, Rizal 4.2
India, Mizoram 47.2 Saudi Arabia, Riyadh, Saudi 3.5
Chile, Bio Bio 41.4 USA, Utah 3.4
Belarus 30.3 Thailand, Khon Kaen 3.0
Colombia, Pasto 26.5 India, Poona 3.0
Russian Federation, Samara 25.7 Malaysia, Penang, Malay 2.9
USA, Los Angeles, Korean 24.4 Kuwait 2.6
Costa Rica 20.9 South Africa, Eastern Cape 1.4
ASR, age-standardised rate per 100,000 person-years.
Figure 4, based on the first ten volumes of CI5 [4], shows the trends in age-standardised incidence
rates for males and females for selected populations covering the period 1960–2005. Over the 45-year
period, incidence rates have steadily declined in nearly all populations with similar trends in both
males and females. The downward trends can be observed regardless of the level of background
risk and, even in areas with historically very high gastric cancer rates such as Japan and Colombia,
decreasing trends can be observed in recent years. Despite the global decline in incidence rates over
many years, the absolute burden of gastric cancer (number of cases diagnosed) has remained high as
a result of population growth and ageing. Indeed, even if gastric cancer rates continue to decline at
around the present level of approximately −2% per annum, the absolute burden is likely to remain
static for the next 10–20 years because of these demographic factors (Table 2).
Figure 4. Gastric cancer: age-standardised (world) incidence rates by year for cancer registries in CI5
I-X (Source: Cancer Incidence in Five Continents, CI5plus, adapted from [4], 2014, International Agency
for Research on Cancer). (a) Males (all ages); (b) Females (all ages).
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Table 2. Predicted gastric cancer burden 2012–2030 (Source: GLOBOCAN 2012, adapted from [1], 2013,
International Agency for Research on Cancer).
Year No. Gastric Cancers (Millions)
Demographic Effect Demographic and−2.0% APC
2012 0.95 0.95
2015 1.03 0.97
2020 1.17 1.00
2025 1.34 1.03
2030 1.52 1.06
In general, the distribution of gastric cancer by subsite of the stomach has not been well
characterised in international comparative datasets. A recent estimate of the proportion of cardia and
non-cardia gastric cancers using the same data sources as above indicates that approximately 27% of
gastric cancers (260,000 of the 952,000 worldwide) arise in the cardia region of the stomach with the
remaining 73% (691,000) defined as non-cardia [5]. The geographic variation of the two subsites is
broadly similar with the highest rates estimated to occur in Asia. However, whereas most populations
show higher rates of non-cardia cancer, this is not consistently the case and in some countries, such as
Australia, the USA and the UK, rates are similar to each other [5].
2. The Association of Gastric Cancer with Helicobacter pylori Infection
2.1. Evaluation by International Agency for Research on Cancer (IARC) Working Groups
Helicobacter pylori was initially considered and classified as carcinogenic to humans (Group I
carcinogen) by an International Agency for Research on Cancer (IARC) Working Group in 1994 based
on the results from a small number of studies then available (four cohort and nine case–control) that
considered gastric carcinoma [6]. In 2009, a new Working Group reviewed considerably more data
which had become available since the previous evaluation and reconfirmed that chronic infection with
H. pylori is a Group 1 carcinogen with sufficient evidence of causing non-cardia gastric carcinoma and
low-grade B-cell gastric MALT lymphoma.
In 2009, a new Working Group reviewed considerably more data which had become available
since the previous evaluation and reconfirmed that chronic infection with H. pylori is a Group 1
carcinogen with sufficient evidence of causing non-cardia gastric carcinoma and low-grade B-cell
gastric MALT lymphoma [7].
2.2. Quantification of Risk—Comparison of Western Blot and Serology Data
The 2009 Working Group noted a substantial increase in the estimated odds ratios (ORs) for the
association between H. pylori infection and non-cardia gastric carcinoma in studies using Western
blotting assays compared with enzyme-linked immunosorbent assay (ELISA) for the analysis of serum
IgG responses to H. pylori. Using ELISAs, statistically significant ORs varied widely from 1.6 to 7.9,
whilst studies using Western blotting analysis to determine infection status reported an increase in the
ORs up to 10.6 [8] or 17.8 [9]. This observation was later re-confirmed in a nested case–control study
of the European Prospective Investigation into Cancer and Nutrition study (Eurgast-EPIC), which
showed that the magnitude of the non-cardia gastric cancer risk associated with H. pylori infection in
IgG serological studies was more than three-fold higher by Western blot assay than by ELISA (OR was
21.4 and 6.8 by immunoblot and ELISA, respectively) [10]. Earlier Western blotting analysis of both
IgG serological and gastric mucosal IgA responses to H. pylori have also been investigated. Resected
non-involved gastric mucosa of patients with gastric cancer was cultured in vitro to investigate mucosal
IgA responses to H. pylori. Interestingly, several H. pylori IgG serological negative patients with gastric
cancer secreted mucosal IgA against multiple H. pylori proteins indicative of a previous positive
H. pylori status [11].
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2.3. Other Evidence: Animal Studies/Mechanistic Understanding
The IARC Working Group evaluation also considered experimental evidence in Mongolian gerbils
and mice and concluded that there is sufficient evidence for the carcinogenicity of infection with
H. pylori in experimental rodent models [7]. H. pylori-infected Mongolian gerbils developed gastric
adenocarcinoma in the majority of studies [12–18] (Figure 5). However, in inbred mice with H. pylori
infection, gastritis was evident whilst gastric adenocarcinoma did not develop [19–21]. In several
transgenic mice, such as TGF-β deficient [22], p27 deficient [23] and Trefoil factor family 2 (TFF2)
deficient [24], infection with H. pylori showed synergistic effects in gastric cancer development [7].
In addition, H. pylori infection of transgenic mice overexpressing gastrin could induce gastric
adenocarcinoma [25], while gastric carcinogenesis was inhibited when H. pylori eradication therapy
was introduced [26]. H. pylori eradication in mice deficient in p27 similarly reversed premalignant
lesions [27].
Figure 5. Histopathology of gastric mucosa of Mongolian gerbils infected with 3GX Chinese strain
of Helicobacter pylori. Adapted from the Journal of Pathology [28], 2006, Wiley. Haematoxylin
and eosin-stained sections of corpus gastric mucosa of Mongolian gerbils 30 weeks post-infection
with H. pylori strain 3GX. (A) High-grade dysplasia involving intramucosal and herniating glands.
Bar = 50 µm; (B) Breakup of the architecture of intramucosal glands with isolated clusters of epithelial
cells in the lamina propria indicative of intramucosal carcinoma. Bar = 100 µm.
The Mongolian gerbil model, in which H. pylori-induced gastric pathology progresses from antral
gastritis to pan gastritis with corpus atrophy in a similar manner to human gastric pathology, in
H. pylori infected individuals [28,29] has also been used to assess the effects of H. pylori eradication
on the development of gastric cancer [17]. In addition, following the identification that H. pylori
transactivates the epidermal growth factor receptor (EGFR) in gastric epithelial cells [30,31], the
therapeutic effects of EGFR inhibitors on H. pylori-induced pathology have been examined in gerbil and
murine models. Treatment of H. pylori-infected gerbils with the selective EGFR inhibitor EKB-569 for
32 weeks significantly reduced corpus atrophy, mucous metaplasia, submucosal herniations (Figure 6)
and markedly reduced gastric epithelial cell proliferation to apoptosis ratios [32]. The submucosal
herniations are thus a consequence of changes in epithelial kinetics and dependent on EGFR
transactivation. Recent studies have also indicated that short-term treatment with the EGFR inhibitor
gefitinib reduced DNA damage and gastric inflammation in H. pylori-infected mice and gerbils [33].
These therapeutic studies have shed light on important mechanisms by which H. pylori eradication
therapy and the targeting of key pro-carcinogenic H. pylori-induced signalling pathways, such as EGFR
transactivation, may protect against H. pylori gastric carcinogenesis.
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Figure 6. Pathology of gastric mucosa of H. pylori-infected Mongolian gerbils treated with an epidermal
growth factor receptor (EGFR) inhibitor diet and control diet. Haematoxylin and eosin-stained
sections of gastric antral mucosa of Mongolian gerbils 38 weeks post-infection with H. pylori SS1
strain. (A) H. pylori-infected gerbil on the control diet. Bar = 800 µm. White arrows indicate the
muscularis mucosa, which is discontinuous on the right-hand side, and the three black arrows indicate
large submucosal herniations. The right-hand side herniation is sectioned longitudinally reaching the
gastric lumen. (B) Antral mucosa of H. pylori-infected gerbil on the EKB-569 diet lack submucosal
herniations but have an intact muscularis mucosa (MM) indicated by the white arrow. Bar = 100 µm.
Reproduced with permission of Pathogens [32], 2013, MDPI.
3. H. pylori Infection: Geographic and Time Trends
H. pylori infection is known to be common with a global prevalence of over 50%; however, there
is substantial country-to-country variation. A recent systematic review of 37 studies with national
coverage in 22 countries reported a prevalence of approximately 70% or higher around age 60 years in
Central and South America and Asia in the late 1990s and early 2000s, with a decreasing trend in most
countries where data are available for different time periods [34]. The prevalence of H. pylori infection
was at least two-fold higher in countries with high gastric cancer incidence, both in young adults and
in older participants, compared with countries with a lower background risk [34].
A combination of the high prevalence of H. pylori infection and the subsequent high OR for
the association with gastric cancer results in a high attributable risk. Based on the 952,000 new
gastric cancers diagnosed each year globally, it has recently been estimated that 753,000 (79%) of these
could be attributed to H. pylori infection with a further 13,000 gastric lymphomas also likely to be
H. pylori-associated [35]. These estimates were based on a prevalence of H. pylori infection in gastric
non-cardia cancer cases of 94.6% and a relative risk of 17.0. These estimates indicate that H. pylori
infection should be considered the primary risk factor for gastric cancer, and it has been proposed that
infection might be considered “a (close to) necessary cause of non-cardia gastric cancer” [36].
4. H. pylori Strain Variation and Gastric Cancer Risk
4.1. CagA and the Cag Pathogenicity Island
Early studies found that not all H. pylori strains expressed a protein of circa 120 K and mucosal
IgA responses to this protein are significantly associated with peptic ulcer disease and with active
gastritis characterised by increased gastric epithelial neutrophil infiltration [37]. The 120 K protein,
subsequently called CagA, was identified as a product of the multigene cag pathogenicity island
(cag PAI), a type IV secretory system [38,39]. CagA, which is considered an oncoprotein, is translocated
into gastric epithelial cells by the type IV secretory system of the pathogen, inducing multiple
signalling cascades [40,41]. Other reviews in this series detail the epithelial intracellular signalling
responses induced by CagA and its role in disease pathogenesis [42,43]. The cag PAI also translocates
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peptidoglycan breakdown products into gastric epithelial cells, which activate intracellular NOD1 and
NFκB [44,45], thus contributing to enhanced C-X-C chemokine responses and active gastritis in cag
PAI-positive infections [37,44–46].
Recent studies have reported that in addition to NOD-1 activation, bacterial heptose-1,7-
bisphosphate (HBP), a metabolic precursor of lipopolysaccharide biosynthesis, is also delivered
via the cag type IV secretory system into epithelial cells [47,48]. Independently of NOD1, HBP
activates cytosolic tumour necrosis factor receptor-associated factor (TRAF) interacting protein with
forkhead-associated protein (TIFA), which results in early activation of NFκB and C-X-C chemokine
responses. Thus, activation of epithelial NOD-1 and TIFA by two independent components of H. pylori
delivered via the cag type IV secretory system triggers innate immune inflammatory responses.
4.2. CagA Serology and Corpus Atrophic Gastritis
The CagA protein is immunodominant and is recognised immunologically early following
infection with H. pylori CagA-positive strains by both gastric mucosal IgA and serum IgG responses [49].
With the availability of recombinant CagA [50,51], ELISA assays to determine CagA IgG seropositivity
in the gastric cancer precursor condition corpus atrophy and non-cardia gastric cancer has been the
focus of many studies. Several studies have examined the association of CagA IgG seropositivity with
corpus atrophic gastritis diagnosed pathologically following endoscopic investigation [22–25,52–55].
Other studies have been undertaken in non-endoscoped subjects where the ratio of serum pepsinogen
A and pepsinogen C, an established marker of gastric corpus atrophy, has been measured in the
absence of histological diagnosis [56,57].
Followup endoscopic studies on corpus atrophy-negative H. pylori-positive patients after a time
span of 11 years reported 62% of CagA IgG seropositive subjects (n = 24) had developed atrophic
gastritis versus 32% of H. pylori-positive CagA IgG seronegative subjects (n = 34) (OR = 3.48; 95% CI:
1.02–12.18) [52]. In dyspeptic H. pylori positive patients (n = 267) undergoing endoscopy in 14 European
countries, the combined presence of IgG antibodies to CagA and the H. pylori vacuolating cytotoxin A
(VacA) was also significantly associated with atrophic corpus gastritis (OR = 3.09, 95% CI: 1.26–7.56) [55].
Infection with CagA-positive strains is thus associated with increased risk of developing atrophic
corpus gastritis compared to CagA-negative H. pylori-positive subjects. Supporting evidence comes
from animal studies. Infection of Mongolian gerbils with a wild-type H. pylori strain with a functional
cag type IV secretory system and isogenic mutant strains lacking cagA or cagY indicate that a functional
cag PAI facilitates corpus colonisation and corpus atrophy [58].
The Eurogast study included 17 centres in 13 counties with 2850 randomly selected subjects in
whom serum pepsinogen A/C ratio was determined as a marker of corpus atrophy [56]. Assays for
CagA IgG seropositivity in all 17 centres in the Eurogast study found that H. pylori IgG seropositive
subjects who were CagA seropositive had significantly lower pepsinogen A/C ratios than H. pylori
seropositive subjects who were CagA seronegative. These studies reinforce the association of
CagA-positive strains with corpus atrophy in multiple European countries [56].
The majority of studies on the association of CagA-positive H. pylori infection and corpus atrophy
have to date been undertaken in developed countries. In developing countries, factors that may
beneficially modulate H. pylori-induced pathology are co-infection with helminths, which increase T
regulatory cells and polarise inflammation to Th2 responses [59]. Clinical evidence in H. pylori-infected
Chinese subjects in the Dongting Lake area indicate that co-infection with the digenean helminth
Schistosoma japonicum significantly reduces gastric atrophy in H. pylori-infected subjects as determined
by increased pepsinogen A:pepsinogen C ratio in CagA seronegative subjects [57]. Further studies
from developing countries on the effects of co-infections and their impact on the progression of
CagA-positive H. pylori-associated corpus gastritis are required.
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4.3. CagA Seropositivity and Risk of Non-Cardia Gastric Cancer
The marked global variation in both the incidence of gastric cancer ([1–3], Table 1) and the global
variability in the frequency of cag PAI-positive H. pylori strains [60] are important factors to consider
when assessing the relative risk of infection with CagA-positive H. pylori strains and distal gastric
cancer. Functional differences in CagA tyrosine phosphorylation sites between Eastern and Western
CagA-positive H. pylori strains are evident [61,62]. Recent studies indicate that CagA EPIYA-D in
East Asian strains binds to the pro-oncogenic SHP2 phosphatase 100-fold more strongly than CagA
EPIYA-C in Western H. pylori strains and also stimulates stronger cellular Ras–ERK activation [63].
CagA IgG serological status has been evaluated by ELISA using recombinant CagA in several gastric
cancer case–control and cross-sectional studies to determine whether CagA IgG seropositivity is
associated with an increased incidence of non-cardia gastric cancer relative to CagA seronegative
H. pylori-positive individuals and age-matched uninfected controls [64–69].
In two gastric cancer case–control studies [64,65] serum samples were available from 13–14 years
before the diagnosis of gastric cancer. In a study of 261 Japanese American men with distal
intestinal-type gastric cancer, H. pylori-positive CagA-negative subjects had an OR of 2.7 (95% CI:
1.3–5.6) for intestinal-type gastric cancer compared to uninfected controls [64]. Men who were both
H. pylori and CagA seropositive however had an increased risk of intestinal-type gastric cancer with an
OR of 4.1 (95% CI: 2.2–7.7) [64]. In the second study, 179 North American subjects infected with H. pylori
who were CagA seropositive similarly had increased risk of gastric cancer (OR = 5.8, 95% CI: 2.6–13)
relative to uninfected controls [65]. This increased risk was evident in both intestinal-type gastric cancer
(OR = 5.1, 95% CI: 2.1–12.2) and diffuse-type gastric cancer (OR = 10.1, 95% CI: 2.2–47.4). An endoscopic
study [66] in 81 indigenous Japanese diagnosed with gastric cancer and gender- and age-matched
endoscopic controls reported that CagA seropositivity was significantly increased (p < 0.05) in patients
with gastric cancer relative to non-cancer controls. The risk of gastric cancer with CagA seropositivity
(OR = 1.93, 95% CI: 1.01–3.68) was lower than that in an earlier study [64] in emigrant Japanese men.
The serum samples in the endoscopic study were taken at the time of diagnosis [66], in contrast
to several years before diagnosis in the study of Nomura et al. [64]. Increasing gastric intestinal
metaplasia with long-term H. pylori infection will decrease the density of H. pylori infection and thus
CagA serological positivity. Furthermore, the high frequency of CagA-positive strains in Asia [60] may
impact the assessment of the relative risk of gastric cancer.
A study in 103 younger (<40 years) Japanese patients with gastric cancer and age-matched controls
found both H. pylori-positive CagA seronegative and H. pylori-positive CagA seropositive had an
increased OR of gastric cancer [67]. The majority of these young Japanese patients had diffuse-type
gastric cancer, the epidemiology of which differs from intestinal-type gastric cancer. In contrast to the
studies in Japan, a European study in nine countries found that CagA positivity was associated with a
6.5-fold OR for non-cardia gastric cancer (OR = 6.5, 95% CI: 3.3–12.6) compared to H. pylori-positive
CagA seronegative subjects [68].
Ethnic differences in CagA antibody responses in non-cardia gastric cancer in two Brazilian
case–control groups have also been reported [69]. One group consisted of non-Japanese Brazilians
(178 cancers, 178 controls) and the other group consisted of Japanese Brazilians (80 cancers, 160 controls).
The study used a commercial European CagA ELISA. Higher CagA antibody titres were observed in
non-Japanese Brazilians than Japanese Brazilians, probably reflecting differences in Asian and Western
CagA [60–63]. The OR of non-cardia gastric cancer in CagA seropositives was higher in non-Japanese
Brazilians (OR = 4.5, 95% CI: 2.6–7.8) than in Japanese Brazilians (OR = 2.1, 95% CI: 1.2–3.6) [69]).
Interestingly, in both ethnic groups, the OR of non-cardia gastric cancer was highest in groups with
low positive CagA antibody titres, which would be consistent with a reduced bacterial load in severe
corpus atrophy. Similar observations were made by Suzuki et al. who found in a Japanese population
that the relative risk (RR) of non-cardia gastric cancer in H. pylori seropositives with positive low CagA
antibody titres was greater (RR = 3.9; p < 0.001) than that of subjects with high CagA antibody titres
(RR = 2.0; p = 0.002) [70].
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Meta-analysis of CagA serology determined in 10 non-cardia gastric cancer case–control studies
with age- and gender-matched controls reported CagA seropositivity irrespective of H. pylori status
was 62.8% in cases (n = 1707) and 37.5% in controls (n = 2124). CagA seropositivity increased the
risk of gastric cancer (OR = 2.87, 95% CI: 1.95–4.22) relative to the risk of H. pylori infection alone
(OR = 2.31, 95% CI: 1.58–3.39) [71]. A more recent meta-analysis of 10 gastric cancer case–control
studies with 4325 patients in East Asian countries similarly identified that CagA seropositivity was also
associated with increased risk of developing gastric cancer [72]. However, the OR in the meta-analysis
in East Asian countries (OR = 1.81, 95% CI: 1.30–2.11) was lower than that in the meta-analysis of
Huang et al. [71], which included Western populations.
4.4. Cholesterol Reduction Impacts on H. pylori-Induced Gastric Cancer Risk.
The use of certain pharmacological agents may also affect the outcomes of gastric cancer
case–control studies investigating CagA seropositivity. The translocation of CagA and peptidoglycan
breakdown products/ HBP into gastric epithelial cells via the cag PAI is key in triggering, respectively,
oncogenic signalling pathways and inflammatory innate responses via NFkB activation (see Section 4.1).
H. pylori-induced CagA translocation and induction of IL-8 in gastric epithelial cells can be reduced
by cholesterol depletion [73,74], suggesting that long-term treatment with statins to reduce serum
cholesterol levels could modify H. pylori signalling responses and pathogenesis. In a large case–control
study of 19,728 Taiwanese with gastric cancer, and similar number of controls, previous long-term
treatment with simvastatin was shown to significantly reduce the risk of gastric cancer (OR = 0.76,
95% CI: 0.70–0.83) after adjusting for H. pylori infection, gastric diseases, gastroesophageal reflux
disease, gastric polyp, and gastritis. Those subjects with distal gastric cancer (n = 4539) who had
received previous long-term treatment with simvastatin had a relative risk of 0.65 (95% CI: 0.57–0.75)
of gastric cancer compared to controls who had not received previous long-term treatment with
simvastatin [73]. These studies emphasise the importance of collecting pharmacological data in
case–control studies investigating H. pylori and gastric cancer risk.
4.5. Lack of Association of CagA Seropositivity with Oesophageal Adenocarcinoma
Whilst most studies to date have focused on H. pylori CagA seropositivity and risk of distal
gastric cancer, other important epidemiological studies have examined the association of CagA
seropositivity with oesophageal adenocarcinoma (OAC) and oesophageal squamous cell carcinoma
(OSCC). In contrast to gastric cancer, which is decreasing in many developed countries with the
reduction in H. pylori infection, OAC is increasing. Ye et al. [75] in a population case–control study
in Sweden examined CagA IgG seropositivity in 97 patients with OAC, 85 patients with OSCC, and
499 controls. CagA positivity was associated with a reduced risk of OAC (OR = 0.5; 95% CI: 0.3–0.8).
In contrast, CagA antibody positivity and gastric atrophy were associated with increased OSCC
(OR = 2.1, 95% CI: 1.1–4.0). Wu at al [76] in a population-based case–control study in Los Angeles
examined the association of CagA seropositivity with distal gastric cancer (n = 127) and OAC (n = 80).
Whilst finding a significant association of H. pylori and CagA seropositivity compared to H. pylori
seronegativity with distal gastric cancer (OR = 2.2, 95% CI: 1.13–4.26), no association was evident
between CagA seropositivity and OAC [76]. The above studies suggest that CagA is not associated
with OAC, supporting the hypothesis that cagA+ strains may be protective by reducing OAC [77],
potentially by modifying gastric physiological responses.
An interesting study examining retrospective cohorts of 61,548 unoperated patients with duodenal
ulcers and 81,379 unoperated patients with gastric ulcers in the Swedish Inpatient Register surprisingly
showed patients with duodenal ulcers had a 70% higher risk of OAC (standardised incidence ratio
(SIR) = 1.7, 95% CI: 1.1–2.5) [78]. Gastric ulcers were unrelated to OAC (SIR = 1.1, 95% CI: 0.6–1.7)
but were associated with an 80% increased risk of OSCC (SIR = 1.8, 95% CI: 1.4–2.3). In contrast, in
patients with duodenal ulcers, there was a small excess with OSCC (SIR = 1.3, 95% CI: 0.96–1.8) [78].
Patients with duodenal ulcers have antral predominant gastritis and do not develop atrophic
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gastritis in the gastric corpus mucosa. The above differences in OAC and OSCC risk with H. pylori
infection in subjects with duodenal or gastric ulcers likely reflect different patterns of H. pylori gastric
colonisation, acid secretion and associated genetic variation in acid regulatory cytokines [28], as well
as environmental factors such as smoking.
4.6. Microbiological Evidence Linking CagA/cag PAI Strains with Gastric Cancer
CagA has been recognised as an important factor in the development of gastric cancer in
H. pylori-infected individuals. In a gerbil model, infection with a cagA-positive strain, but not the
isogenic cagA mutant, resulted in development of gastric cancer [13]. Individuals infected with
cagA-positive strains develop gastric cancer in Western populations [11,64,65]. However, in East Asian
countries, most H. pylori strains express cagA; therefore, CagA status alone cannot explain the clinical
outcomes [79]. The mosaicism of the CagA N-terminal repeat region on the residue Glu-Pro-Ile-Tyr-Ala
(EPIYA) motif and its surrounding region categorise the EPIYA segment, known as EPIYA-A,-B
and -C/-D, and can discriminate respectively Western-type CagA and East Asian-type CagA [80].
Epidemiological observations indicate that individuals infected with East Asian-type CagA H. pylori
strains have a closer association with gastric mucosal atrophy and higher incidence of gastric cancer
than Western-type CagA H. pylori strains [81–83]. This different cluster of CagA was also associated
with a different cluster of the cag PAI, known as the Japanese cluster. Individuals infected with the
Japanese cluster strains were reported to have higher atrophic gastritis scores than the Western type
counterpart [84]. Epithelial translocated East Asian-type CagA also has a stronger binding to the host
SHP2 domain, suggesting an increased signalling cascade in host epithelial cells [85].
4.7. Environmental Factors Regulating H. pylori CagA Expression
Apart from the internal mosaicism of CagA, which may reveal different activity of this
oncogenic protein, environmental factors are also important in the regulation of CagA expression.
Reported environmental factors that may be important are pH, salt and host serum iron
concentrations [86–88]. The first observation of pH modifying cagA expression was undertaken
using array studies. The cagA expression was significantly higher at pH 6.0 compared to pH 7.0 [86];
a similarly higher cagA expression was also observed at pH 4.0 [89]. In a recent study, differential
RNA-seq was introduced to characterise the transcriptome expression in H. pylori. This study indicated
that the expression of cagA, determined by the amount of cDNA, was two-fold higher under acid–stress
conditions (pH 5.2) compared to a neutral environment (pH 7.0) [90]. However, the low pH has
advantages to the host, reducing the survival of H. pylori, especially strains with a high number of
EPIYA repeat regions [91].
High salt diets have been shown in epidemiological studies to be associated with an increased
risk of gastric cancer. Intriguingly, recent studies indicated that a high salt diet modifies the expression
of CagA in H. pylori [88]. High salt concentrations increased H. pylori CagA/cagA at both a protein and
transcriptome level. RNA array analysis indicated cagA transcription had a two-fold increase in high
salt concentrations [88]. Subsequent analysis using RT-qPCR methods also showed an increased cagA
transcriptome [92]. Increasing expression of CagA was also observed by protein analysis. In addition,
high salt concentrations mediated effectively the translocation process of CagA into AGS gastric
epithelial cells [88]. High salt conditions also affected the expression of cagA in in vivo studies.
In cagA-positive H. pylori-infected gerbils, a high salt diet induced higher cagA expression compared
to H. pylori-infected gerbils on a regular diet. The gerbil group on a high salt diet infected with
cagA-positive H. pylori strains had higher levels of inflammatory cytokines (IL-1, IL-6, IL-17, and gamma
interferon [IFN-γ]), anti-inflammatory cytokines (IL-10), chemokines (KC, CCL12), and inducible nitric
oxide synthase (iNOS). The higher expression of the H. pylori CagA oncogenic protein and the enhanced
host immune response resulted in higher inflammation scores as well as a higher frequency of gastric
carcinoma [92].
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There is epidemiological evidence of a decreased risk of gastric cancer in subjects with a high
iron status [93]. Iron has also recently been reported to have an association with CagA regulation.
An animal model was used to examine the role of iron deficiency on CagA expression. Iron-depleted
gerbils upregulated CagA expression 1.5 fold compared to expression in iron-replete gerbils [87].
Increased CagA expression was also concomitant with an increased assembly of the cag type IV
secretion system, almost 2-fold higher, in nine visualised pili on strains from iron-replete versus 17
visualised pili on strains from iron-depleted gerbils. The translocation of CagA into gastric epithelial
cells was also increased. Gerbils on iron-depleted diet infected with wild-type H. pylori, but not the
cagA-negative isogenic mutant, were significantly quicker to develop dysplasia and adenocarcinoma
(within 6 weeks of infection) than iron-replete gerbils [87]. In addition, clinically decreasing
serum ferritin levels was inversely associated with premalignant lesions [87]. These data suggest
CagA-positive infections and iron-depleted conditions have a significant role in the development of
gastric cancer.
A subsequent study in iron-depleted gerbils indicated that cagA-negative H. pylori transform
into the coccoid form, a non-viable H. pylori morphology, suggesting that CagA provides an
advantage to the viability of H. pylori [94]. Interestingly, the hypervirulent strains, as a result of
colonisation under iron-depleted conditions, had significantly decreased levels of CagA expression
and epithelial translocation after passaging several times, suggesting the hypervirulent phenotype can
be reversed [94]. These studies [87,94] demonstrate host iron stores can have an important impact on
H. pylori-related gastro-duodenal diseases and suggest iron-deficient subjects may have increased risk
of developing gastric cancer.
5. H. pylori Eradication for Gastric Cancer Prevention
5.1. Critical Evidence: Prospective Studies and Trials
The strong evidence for the carcinogenicity of chronic H. pylori infection suggests a clear
path to preventing gastric cancer cases through eradication of the infection [95]. Population-based
search-and-treat H. pylori programmes have, therefore, been proposed as a means to prevent gastric
cancer [96], and international consensus and guidelines have included this strategy for gastric cancer
prevention, especially in communities at high risk [97,98]. However, no country has yet implemented
such programmes, partly due to lack of confidence in the effectiveness of H. pylori eradication in
reducing gastric cancer and uncertainty about the possible harm of mass antibiotic treatment and its
impact on gut microbiota [95].
The current scientific evidence that gastric cancer risk is reduced by H. pylori eradication is based
on a small number of randomised controlled trials (RCT) of limited to moderate quality in healthy
asymptomatic infected (mainly Asian) individuals [99]. A systematic review and meta-analysis of six
RCTs suggest that searching for and eradicating H. pylori infection reduces the subsequent incidence of
gastric cancer with a pooled relative risk of 0.66 (95% CI: 0.46–0.95) [99]. The authors noted that these
data cannot necessarily be extrapolated to other populations as all except one study was conducted in
East Asia [99].
A more recent systematic review and meta-analysis of 24 prospective studies also concluded that
individuals receiving H. pylori eradication therapy had a lower incidence rate of gastric cancer than
those without eradication therapy (a pooled rate ratio of 0.53 (95% CI: 0.44–0.64) after adjustment for
baseline gastric cancer incidence) [100]. Subgroup analyses showed greater benefit among individuals
after endoscopic resection of gastric cancers (pooled incidence rate ratio based on two RCTs and
eight cohort studies, 0.46; 95% CI: 0.35–0.60) than among asymptomatic infected individuals (pooled
incidence rate ratio based on six RCTs and eight cohort studies, 0.62; 95% CI: 0.49–0.79), however, with
no statistical difference between the two [100]. This study also noted that the quantitative benefit of
H. pylori eradication was greater in studies with higher baseline incidence rates of gastric cancer.
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Despite the observed preventive effect of H. pylori eradication in gastric cancer, potential
adverse consequences of mass therapy with antibiotics—for example, short- and long-term changes
in the normal human microbiota, weight gain, gastroesophageal reflux disease and antibiotic
resistance—have not been addressed in previous studies. In addition, before implementing
large-scale programmes, further investigations are required regarding programme costs, feasibility,
and appropriate target groups for the intervention, as well as region-specific data.
Several clinical trials that are currently underway should help clarify whether and how to
implement population-based H. pylori screening and treatment programmes and should resolve
many related uncertainties. The largest of these was initiated in 2011 in Linqu County in China
with 184,786 residents aged 25–54 from a high-risk population [101]. H. pylori-positive participants
ascertained by 13C-urea breath test were assigned to one of two groups receiving either a 10-day
quadruple anti-H. pylori treatment or lookalike placebo together with a single dose of omeprazole
and bismuth.
In the UK, the H. pylori Screening Study was initiated in 1997 to assess whether screening for and
eradicating H. pylori infection in 56,000 healthy men aged 35–69 and women aged 45–69 would reduce
the incidence of gastric cancer with a planned followup of 15 years or more after recruitment [102].
A multicentre randomised study to evaluate whether H. pylori screening followed by eradication in
infected participants and endoscopy of those with serological evidence of atrophic gastritis could
reduce gastric cancer mortality continues, recruiting in Latvia and potentially in neighbouring countries
with the target number of 30,000 after completion of its pilot phase in 2016 [103]. In the Republic of
Korea, a multicentre, double-blind randomised controlled trial to evaluate the preventive efficacy and
effectiveness of H. pylori treatment on gastric cancer among 40–65 year-old participants recruited from
the nationwide cancer screening programme was launched in 2014. The trial with a target number
of 11,000 participants is scheduled to run for 10 years with biennial endoscopic followup within the
screening programmes and populations [104].
Whilst there are concerns regarding increasing H. pylori antibiotic resistance [105] and other
adverse events as noted above, standard H. pylori antibiotic eradication therapies have been evaluated
in multiple clinical studies before their application in controlled trials to evaluate their impact on
gastric cancer. To date, no other clinically validated approach for the eradication of H. pylori is currently
available, despite extensive preclinical vaccine studies on preventative and therapeutic H. pylori
vaccines [106,107]. Future strategies could investigate, for example, targeting CagA interactions
with key cellular tumour suppressor proteins, such as the apoptosis-stimulating protein of p53-2
(ASPP2) [108]. CagA binding to ASPP2 blocks ASPP2 binding to the tumour suppressor p53 [108].
Modelling of CagA–ASPP2 interactions may facilitate the identification of small peptide inhibitors
that could block CagA-induced deregulation of tumour suppressors [108].
5.2. Strategies for Eradication of H. pylori Infection and Their Evaluation
In December 2013, a Working Group meeting convened by IARC reviewed the evidence regarding
eradication of H. pylori as a strategy for gastric cancer prevention [109]. The participants in the Working
Group concluded that the high global burden of gastric cancer and the feasibility of treating its principal
cause make it a logical target for intervention [110]. The Group also concluded, from a review of
economic models, that population-based H. pylori screening and treatment would be both feasible and
cost-effective in preventing gastric cancer [111]. The Group recommended that countries explore the
possibility of introducing population-based H. pylori screening and treatment programmes but within
the context of a scientifically valid assessment of programme processes, feasibility, effectiveness and
possible adverse consequences [109,110]. The introduction in regions of high gastric cancer incidence of
population-based H. pylori screening and treatment programmes, with a scientifically valid assessment
of programme processes, feasibility, effectiveness and possible adverse consequences would affect the
incidence of H. pylori-induced gastric cancer.
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Given the recent molecular understanding of the oncogenic role of CagA, targeting H. pylori
screening and treatment programmes in populations with a high incidence of H. pylori CagA-positive
strains, particularly the more oncogenic East Asian H. pylori CagA strains, may be worth further
exploration to optimise the benefits of such programmes.
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